COMMUNIQUÉS West-GlobeNewswire

Soleo Health Introduces State-of-the-Art Pharmacy and Infusion Center in Washington, D.C., Area
14/10/2025
New Location Expands Service and Support to Patients Along Mid-Atlantic Corridor FRISCO, Texas and HERNDON, Va., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Soleo Health , a national provider of complex specialty pharmacy [...]
Teladoc Health Adds Workplace Safety Capability to its AI-Enabled Clarity™ Monitoring Solution for Hospitals and Health Systems
14/10/2025
New capability aims to address the growing threat of workplace violence in healthcare settings, building on the company’s suite of AI-enabled solutions that leverage purpose-built technology to transform care NEW YORK, [...]
Abalos Therapeutics Publishes in Cell Reports Medicine Validating ABX-001’s Potential to Overcome Cancer Immunotherapy Hurdles
14/10/2025
-- Preclinical data support Abalos’ first-in-class approach of safely harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to treat solid tumors -- Düsseldorf, Germany, October 14, 2025 – Abalos [...]
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
14/10/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Tan Shao Weng, Daniel [...]
Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025
14/10/2025
ORION CORPORATION PRESS RELEASE 14 OCTOBER 2025 at 11.15 EEST Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025 Orion will publish Interim Report for January–September 2025 [...]
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
14/10/2025
ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic [...]
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
14/10/2025
ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic [...]
EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases
14/10/2025
Press Release Press Release EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases Through this funding round, the company will initiate the clinical development of its first therapeutic [...]
CancerVax Precision Therapy Successfully Avoids Healthy Liver Cells
14/10/2025
In-vitro studies confirm that the Company’s novel Smart mRNA could drastically reduce off-target liver toxicity, a major issue affecting many cancer drugs Lehi, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, October 14, [...]
Peer Reviewed Publication Provides Evidence for Iron Dysregulation as a Driver of Dry AMD/GA and the Potential of Transferrin to Restore Iron Balance, Reinforcing PulseSight’s Therapeutic Strategy for PST-611
14/10/2025
PARIS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, a clinical stage ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology welcomes [...]
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
14/10/2025
PRESS RELEASE AB SCIENCE RELEASES INITIAL DATA ON THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE FIRST THREE PATIENTS, ALL OF WHOM HAVE AML WITH [...]
AB Science tiendra une conférence virtuelle le jeudi 16 octobre 2025, de 14 h à 15 h CET, afin de faire le point sur l'étude de phase 1 avec AB8939
14/10/2025
COMMUNIQUE DE PRESSE AB SCIENCE COMMUNIQUE LES PREMIERES DONNÉES DE COMBINAISON DE AB8939 AVEC VENETOCLAX : LES TROIS PREMIERS PATIENTS ATTEINTS D’UNE LEUCEMIE MYEOLIDE AIGUES (LMA) ASSOCIES A UN PROFIL GENETIQUE TRES [...]
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
14/10/2025
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the [...]
Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
14/10/2025
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
Apollomics, Inc. Company Operational Continuity Update
14/10/2025
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics is a clinical-stage [...]
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
14/10/2025
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose [...]
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
14/10/2025
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. [...]
Geron Corporation Announces Executive Leadership Transitions and Appointments
13/10/2025
Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial- [...]
MAIA Biotechnology Announces $736,600 Private Placement
13/10/2025
CHICAGO, IL, Oct. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today [...]

Pages